Market Closed -
Nasdaq
04:00:00 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
5.03
USD
|
+3.07%
|
|
-2.33%
|
-19.52%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
186.3
|
467.6
|
597.6
|
173
|
84.56
|
71.75
|
-
|
-
|
Enterprise Value (EV)
1 |
186.3
|
322
|
418.7
|
0.9368
|
84.56
|
71.75
|
71.75
|
71.75
|
P/E ratio
|
-4.89
x
|
-9.53
x
|
-10.1
x
|
-1.93
x
|
-0.8
x
|
-0.98
x
|
-1.15
x
|
-1.34
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.71
x
|
16.5
x
|
14.8
x
|
4.18
x
|
10.2
x
|
13.3
x
|
14.8
x
|
3.57
x
|
EV / Revenue
|
8.71
x
|
16.5
x
|
14.8
x
|
4.18
x
|
10.2
x
|
13.3
x
|
14.8
x
|
3.57
x
|
EV / EBITDA
|
-
|
-13,913,938
x
|
-9,532,389
x
|
-2,030,435
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-23.6
x
|
-6.73
x
|
-1.64
x
|
-
|
-0.91
x
|
-0.7
x
|
-0.51
x
|
FCF Yield
|
-
|
-4.24%
|
-14.9%
|
-61%
|
-
|
-110%
|
-142%
|
-195%
|
Price to Book
|
-
|
6.51
x
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
7,624
|
9,812
|
12,310
|
14,934
|
14,934
|
15,227
|
-
|
-
|
Reference price
2 |
24.44
|
47.65
|
48.55
|
11.59
|
5.663
|
4.712
|
4.712
|
4.712
|
Announcement Date
|
4/28/20
|
4/15/21
|
3/31/22
|
3/23/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
21.39
|
28.36
|
40.37
|
41.35
|
8.275
|
5.389
|
4.832
|
20.11
|
EBITDA
|
-
|
-33.6
|
-62.7
|
-85.22
|
-
|
-
|
-
|
-
|
EBIT
1 |
-32.38
|
-34.72
|
-64.03
|
-88.12
|
-106.7
|
-89.14
|
-109.6
|
-135.7
|
Operating Margin
|
-151.35%
|
-122.42%
|
-158.62%
|
-213.09%
|
-1,288.95%
|
-1,654%
|
-2,268.05%
|
-674.47%
|
Earnings before Tax (EBT)
1 |
-32.36
|
-41.36
|
-57.52
|
-86
|
-105.9
|
-89.22
|
-104.1
|
-130.9
|
Net income
1 |
-32.36
|
-41.37
|
-57.52
|
-86
|
-105.9
|
-88.02
|
-99.42
|
-112.6
|
Net margin
|
-151.3%
|
-145.86%
|
-142.5%
|
-207.98%
|
-1,280.22%
|
-1,633.18%
|
-2,057.55%
|
-559.89%
|
EPS
2 |
-5.000
|
-5.000
|
-4.800
|
-6.000
|
-7.090
|
-4.811
|
-4.112
|
-3.511
|
Free Cash Flow
1 |
-
|
-19.83
|
-88.79
|
-105.6
|
-
|
-79
|
-102
|
-140
|
FCF margin
|
-
|
-69.93%
|
-219.95%
|
-255.24%
|
-
|
-1,465.86%
|
-2,110.96%
|
-696.02%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/28/20
|
4/15/21
|
3/31/22
|
3/23/23
|
3/28/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
8.662
|
10.34
|
8.006
|
7.301
|
14.89
|
11.16
|
4.51
|
1.39
|
1.962
|
0.413
|
1.256
|
1.116
|
1.096
|
1.136
|
-
|
EBITDA
|
-
|
-23.78
|
-
|
-21.31
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-18.57
|
-24.18
|
-17.13
|
-21.66
|
-19.21
|
-30.11
|
-31.46
|
-29.44
|
-24.92
|
-20.84
|
-24.69
|
-24.29
|
-21.79
|
-21.66
|
-
|
Operating Margin
|
-214.37%
|
-233.86%
|
-214.01%
|
-296.7%
|
-129.02%
|
-269.89%
|
-697.58%
|
-2,118.13%
|
-1,270.29%
|
-5,044.79%
|
-1,966.78%
|
-2,177.06%
|
-1,989.36%
|
-1,907.6%
|
-
|
Earnings before Tax (EBT)
1 |
-17.1
|
-23.09
|
-16.66
|
-19.41
|
-16.49
|
-33.44
|
-31.98
|
-29.4
|
-24.36
|
-20.2
|
-23.16
|
-23.15
|
-24.24
|
-23.45
|
-
|
Net income
1 |
-17.1
|
-23.09
|
-16.66
|
-19.41
|
-16.49
|
-33.44
|
-31.98
|
-29.4
|
-24.36
|
-20.2
|
-24.12
|
-23.86
|
-21.68
|
-21.09
|
-
|
Net margin
|
-197.36%
|
-223.33%
|
-208.16%
|
-265.84%
|
-110.76%
|
-299.7%
|
-709.16%
|
-2,114.75%
|
-1,241.34%
|
-4,892.25%
|
-1,920.88%
|
-2,139.07%
|
-1,979.17%
|
-1,857.29%
|
-
|
EPS
2 |
-1.400
|
-1.900
|
-1.400
|
-1.300
|
-1.100
|
-2.200
|
-2.100
|
-2.000
|
-1.600
|
-6.520
|
-1.547
|
-1.282
|
-1.105
|
-1.068
|
-0.8150
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/31/22
|
6/1/22
|
8/11/22
|
11/15/22
|
3/23/23
|
5/23/23
|
8/10/23
|
11/14/23
|
3/28/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
146
|
179
|
172
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-19.8
|
-88.8
|
-106
|
-
|
-79
|
-102
|
-140
|
ROE (net income / shareholders' equity)
|
-
|
-74.8%
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
7.330
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-2.320
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
0.43
|
2.2
|
0.66
|
3.73
|
1.5
|
1.5
|
2
|
Capex / Sales
|
-
|
1.52%
|
5.44%
|
1.59%
|
45.06%
|
27.83%
|
31.04%
|
9.94%
|
Announcement Date
|
4/28/20
|
4/15/21
|
3/31/22
|
3/23/23
|
3/28/24
|
-
|
-
|
-
|
Last Close Price
4.712
EUR Average target price
20.83
EUR Spread / Average Target +342.11% Consensus |
1st Jan change
|
Capi.
|
---|
| -19.52% | 76.59M | | -2.31% | 103B | | +0.56% | 95.28B | | +1.69% | 22.15B | | -17.37% | 21.02B | | -9.30% | 18.15B | | -41.01% | 16.74B | | -14.85% | 16.05B | | +3.21% | 13.68B | | +33.54% | 12.17B |
Bio Therapeutic Drugs
|